AVTX-803 (L-Fucose) for Leukocyte Adhesion Deficiency

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Mayo Clinic, Rochester, MN
Leukocyte Adhesion Deficiency+2 More
AVTX-803 (L-Fucose) - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it works better than current treatment for a rare disease called Leukocyte Adhesion Deficiency, Type II. AVTX-803 (L-Fucose) is a drug used to treat Leukocyte Adhesion Deficiency. This drug was previously approved by the FDA to treat a different condition. In this clinical trial, patients will not receive a placebo.

Eligible Conditions

  • Leukocyte Adhesion Deficiency

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Leukocyte Adhesion Deficiency

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Change from Baseline at Day 56, Change from Baseline at Day 112

Day 112
Effect of AVTX-803 on the percent of leukocytes expressing Sialyl-Lewis X antigen

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Leukocyte Adhesion Deficiency

Trial Design

2 Treatment Groups

Withdrawal
1 of 2
AVTX-803
1 of 2
Active Control
Experimental Treatment

4 Total Participants · 2 Treatment Groups

Primary Treatment: AVTX-803 (L-Fucose) · No Placebo Group · Phase 3

AVTX-803
Drug
Experimental Group · 1 Intervention: AVTX-803 (L-Fucose) · Intervention Types: Drug
WithdrawalNoIntervention Group · 1 Intervention: Withdrawal · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from baseline at day 56, change from baseline at day 112
Closest Location: Mayo Clinic · Rochester, MN
Photo of jacksonville mayo clinic 1Photo of jacksonville mayo clinic 2Photo of jacksonville mayo clinic 3
1989First Recorded Clinical Trial
1 TrialsResearching Leukocyte Adhesion Deficiency
2178 CompletedClinical Trials

Who is running the clinical trial?

Avalo Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
1,908 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have LAD II (SLC35C1-CDG).
You have a history of recurrent infections, opportunistic infections or infections that did not respond well to standard of care treatment.
Subjects or parents (for subjects under legal age for consent) have provided written informed consent for this study
You are non-lactating and have a negative pregnancy test at screening.
You are male and you agree to use an acceptable double-barrier method of contraception with your partner as determined by the investigator or sub-investigator for the duration of the study and 30 days following the last dose of study drug.
Uses an acceptable method of contraception as determined by the investigator or sub-investigator for the duration of the study and 30 days following the last dose of study drug.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.